Introduction
Ticagrelor is an oral, reversibly binding, direct-acting P2Y 12 receptor antagonist. It is approved worldwide for use in acute coronary syndrome (ACS) patients in combination with low-dose aspirin at a loading dose (LD) of 180 mg, followed by maintenance dose (MD) of 90 mg twice daily. In addition, based on the PEGASUS-TIMI 54 study, 1 ticagrelor has been approved at doses of 60 mg twice daily in selected patients of post-myocardial infarction (MI) of one or more years.
Ticagrelor is rapidly absorbed after oral administration and has a predictable pharmacokinetic (PK) profile. 2 Ticagrelor gets metabolized by the cytochrome P450 (CYP) enzyme to AR-C124910XX, a metabolite that possesses equivalent antiplatelet potency as the parent drug. 3, 4 Both ticagrelor and AR-C124910XX bind reversibly to the P2Y 12 receptor and exert their pharmacologic effects. 5 The most common adverse events of ticagrelor are bleeding, dyspnea, gastrointestinal disturbances such as nausea and diarrhea, ventricular pauses $3 sec, and bradycardia. 6, 7 submit your manuscript | www.dovepress.com
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In the PLATO trial, ticagrelor has been compared to clopidogrel for prevention of cardiovascular (CV) events in ACS patients. Ticagrelor was more effective at reducing the composite rate of MI, stroke, or death from vascular causes at 12 months and it had similar rates of major bleeding compared to clopidogrel, but more non-coronary artery bypass grafting-related major bleeding and combined major or minor bleeding were observed. 6 In PHILO, a study designed similar to PLATO but aimed to assess the outcomes of East Asian patients, 801 East Asian patients with ACS who were planned to undergo percutaneous coronary intervention (PCI) were followed up for a mean of 200-210 days. This study found that there were no significant difference between ticagrelor and clopidogrel in clinical efficacy and in major bleeding. However, minor bleeding and composite of major and minor bleeding occurred at a higher rate in the ticagrelor group. 8 From this study, superior efficacy of ticagrelor, as observed in the PLATO trial, was questioned in East Asian patients, and more alarmingly, the risk of higher bleeding rates in the ticagrelor group suggested a need for further evaluation of a lower dose of ticagrelor in East Asian population. 9 Of note, in Japan, other widely used oral P2Y 12 receptor antagonists such as clopidogrel and prasugrel have been approved at lower doses than the doses approved worldwide based on the PK, pharmacodynamic (PD), and clinical studies of these agents in the Japanese population. [10] [11] [12] [13] [14] [15] Clopidogrel, which is approved at MD of 75 mg daily worldwide, is also approved at 75 mg daily in Japan, but it is suggested that 50 mg daily dose can also be used based on patient's age, body weight, and symptoms. 16 Prasugrel, which is approved at LD of 60 mg and MD of 10 mg daily worldwide, is approved at 20 mg LD and 3.75 mg MD doses in Japan. 17 In addition, it was observed that C max and area under the curve (AUC) of ticagrelor were observed to be 48% and 40% higher in Japanese patients compared to Caucasians, respectively. 18 This observance, in accordance with the PHILO trial results of higher risk of bleeding of ticagrelor in East Asian patients, suggests that perhaps a lower dose of ticagrelor could be warranted in East Asian populations in order to minimize the adverse events while maintaining its effectiveness.
Therefore, the aim of this study was to evaluate all available PK/PD and clinical studies involving ticagrelor at standard and reduced doses in East Asian populations to examine whether the use of lower or standard ticagrelor doses would be appropriate in this population.
Methods
Search strategy
Initially, we structured a PICO (population, intervention, comparison, and outcomes) question to guide our literature search. Our PICO question was as follows: In the East Asian population, how does low dose of ticagrelor compared with the standard dose of ticagrelor affect PK/PD results and clinical end points? Therefore, the literature search included terms related to ACS, East Asians, low dose, and ticagrelor (refer to Supplementary material for full search terms).
No limitations in publication dates, language, or article types were specified. We used PubMed, EMBASE, and Cochrane databases for the comprehensive literature search. The search was initially conducted in July 2016 and repeated in April 2017.
Study selection
Literature search was conducted with PubMed (84 articles), EMBASE (503 articles), and Cochrane databases (184 articles). Using the reference management program, RefWorks, 146 duplicate articles were deleted, resulting in a total of 625 articles. Two independent reviewers reviewed the titles and abstracts of the articles for the study selection process. Discrepancies regarding inclusion of articles were discussed and consensus was made with a third reviewer.
We included articles with the following characteristics: 1) prospective studies, 2) studies that compared the standard dose of ticagrelor (180 mg LD and/or 90 mg twice daily MD) to a lower LD and/or MD of ticagrelor, and 3) studies that included mostly East Asians or partially East Asians but with a subgroup analysis on Asian population. We excluded articles with the following characteristics: 1) non-clinical studies, 2) studies that did not include East Asians or those in which the percentage of East Asians included was ,10% of the total study population, and 3) studies that included only patients with special conditions (eg, reduced renal or hepatic function). Reasons for exclusion of articles are shown in Figure 1 . A total of seven articles met the inclusion/exclusion criteria and were included in this analysis.
Data extraction
From each study, drug regimens, number of participants and their race, study design, inclusion/exclusion criteria, PK data (C max , AUC, t 1 
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Results
Seven studies were included in this systematic review, which included healthy subjects, 19, 20 patients with ACS, 21, 22 patients 1-3 years post-MI, 1 and those with stable coronary artery disease. 23, 24 Most of the studies included the half dose of ticagrelor as the low dose (90 mg LD or 45 mg BID MD), although one study also included the 60 mg BID dose of ticagrelor. 24 Of the seven included studies, six studies were conducted in Asia and one study was conducted worldwide including 11.0% of Asians. 1 One article in Chinese was translated into English for analysis. 21 All studies included ticagrelor standard-dose and lower-dose arms, and some also included placebo or clopidogrel standard-dose arms to compare the results. Participants in the study did not take any other antiplatelet or anticoagulant therapy except for the study medication and aspirin, in some cases. Table 1 summarizes the characteristics and the participants included in each study.
PK data
PK data of ticagrelor and AR-C124910XX were available in four studies. LD and MDs were evaluated in three and four of the studies, respectively, which are summarized in Table 2 . In these studies, a common finding was that C max and AUC of ticagrelor and AR-C124910XX increased doseproportionally between 90 mg and 180 mg LDs, 45 mg and 90 mg single doses, and 45 mg BID and 90 mg BID MDs. When the comparison of ticagrelor doses were twofold, the included studies showed that ticagrelor and AR-C124910XX C max increased 1.8-3.1 fold and 1.6-2.9 fold, respectively, and AUC increased 1.9-2.6 fold and 1.7-2.6 fold, respectively. However, in a study by Li et al 24 where 45 mg, 60 mg, and 90 mg doses were compared, although there was a doseproportional increase in C max and AUC between 45 mg and 90 mg doses, differences between ticagrelor 45 and 60 mg were not significant.
PD data
PD data of ticagrelor were available in five studies, where final extent IPA and/or PRU were measured (Table 3) . Three studies observed greater extent of platelet inhibition (higher IPA and/or lower PRU) with higher doses of ticagrelor, whereas in two studies, no significant differences in the extent of platelet inhibition (both measured by PRU) were observed between ticagrelor 45 mg BID and 90 mg BID doses. Four of the studies also compared the final extent IPA and/or PRU with standard dose of clopidogrel. All ticagrelor doses had considerably 23 or significantly [20] [21] [22] more IPA compared to clopidogrel standard dose. In addition, peak mean percentage inhibition of PRU was achieved earlier in ticagrelor (2-4 h) versus clopidogrel (8 h) group. 
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Clinical outcomes: efficacy
Clinical efficacy outcomes were evaluated in two studies (Table 4) . 21, 25 PEGASUS-TIMI 54 is a clinical trial that compared the efficacy and safety of ticagrelor 60 mg BID, 90 mg BID, and placebo in a total of 21,162 patients who are 1-3 years post-MI for a median follow-up of 33 months. 25 Of these, 11.0% of the patients were from Asia. The primary efficacy endpoint of this study was the composite of CV death, MI, or stroke. In ticagrelor 60 mg, 90 mg, and placebo group, this primary efficacy endpoint occurred in 7.77%, 7.85%, and 9.04% of the patients. Both of the ticagrelor groups had significantly less events compared to placebo, but significant differences in the efficacy between the two doses were not observed. When the primary efficacy outcome was analyzed by race and by region, interaction p-value was not statistically significant, indicating that the efficacy outcome was not statistically influenced by race.
Li et al 21 evaluated the efficacy outcomes in 351 Chinese patients with unstable angina pectoris and nonrevascularization. Patients were given either standard-dose or low-dose (90 mg LD/45 mg BID MD) ticagrelor for 12 months. They evaluated the rates of CV death, MI, stroke, PCI, and recurrent angina and found that there were no significant differences in the rates between the ticagrelor doses for all outcomes measured.
Clinical outcomes: safety
All seven studies reported the safety and tolerability data (Table 5 ). In studies that lasted for less than 7 days, no major bleeding was reported. 19, 20, 22, 24 In a study by Li et al, 19 one case of minor bleeding was observed in each of the ticagrelor 90 mg and 180 mg group. In another study by Li et al, 24 ticagrelor 45 mg, 60 mg, and 90 mg had one (8.3%), two (16.7%), and one (8.3%) patients with minor bleeding, respectively. In a study by Xue et al, 22 minor bleeding was observed only in ticagrelor 90 mg group (9.5%). In a study by Li et al, 20 minimal bleeding was reported in one and two patients in ticagrelor low-dose and standard-dose groups, respectively, whereas no cases of minimal bleeding were observed in the clopidogrel group.
Both major and minor bleeding were observed in studies over 4 weeks of duration. 1, 21, 23 In a study by Hiasa et al, 23 stable CAD patients were given ticagrelor 45 mg BID, 90 mg BID, or clopidogrel 75 mg daily for 4 weeks with underlying low-dose aspirin therapy. Only one patient in the low-dose ticagrelor group reported major bleeding. Regarding minimal 
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Lee et al bleeding, ticagrelor 45 mg BID had 26.0%, 90 mg BID had 39.5%, and clopidogrel group had 21.7% incidence. In PEGASUS-TIMI 54, where patients were followed up for a median of 33 months, 2.3% of patients in ticagrelor 60 mg BID group and 2.6% in ticagrelor 90 mg BID group had major bleeding, which were both significantly more compared to the placebo group (1.1%), but statistical significance between the two ticagrelor doses were not reported. When the 
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Evaluation of low-dose ticagrelor in East Asians subgroup of patients from Asia was analyzed, similar results were observed, with the exception of ticagrelor 60 mg BID dose having a higher numerical incidence (3.7%) of major bleeding than ticagrelor 90 mg BID dose (3.0%). 1 In a study by Li et al, 21 patients were followed up for 12 months and major bleeding occurred in 4.6% and 12.1% of patients in the low-and standard-dose ticagrelor groups, respectively, and this difference was statistically significant. Patients in the clopidogrel group had 3.6% incidence of major bleeding, and this rate was not statistically different from the incidence 
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Lee et al observed for low-dose ticagrelor group. Regarding minor bleeding, the low-dose ticagrelor group (5.6%) and clopidogrel group (4.5%) had similar incidence, but standard-dose ticagrelor group had statistically more incidence of minor bleeding (15.9%).
Dyspnea was reported in most of the studies with a trend of increasing incidence with increasing dose, but one study that compared ticagrelor 45 mg (3.7%) to 90 mg (11.4%) found no statistical significance between the two groups (hazards ratio [HR] 1.086, 95% confidence interval [95% CI] 0.952-1.237). 21 Incidence of any adverse events were reported, but its statistical significance is difficult to determine as in some studies, the incidence was numerically similar between ticagrelor doses, but in other cases, more adverse event rates were reported in standard dose of ticagrelor. No statistical analysis on any adverse events was conducted in the seven included studies.
Discussion
Ticagrelor is a potent P2Y 12 receptor antagonist used for the prevention of recurrent ACS in combination with aspirin. Ticagrelor has more potent and consistent antiplatelet effects than clopidogrel, a widely used P2Y 12 receptor antagonist. Clopidogrel is a prodrug that requires two-step metabolism by the CYP enzymes to become an active moiety, and this results in large interpersonal variations in clopidogrel drug response contributory to CYP enzyme polymorphisms. 26, 27 However, in the PHILO study conducted in East Asians, ticagrelor did not demonstrate superior efficacy over clopidogrel and had a trend toward higher major bleeding (HR 1.54, 95% CI 0.94-2.53) and a significantly higher rate of combined major and minor bleeding (HR 1.72, 95% CI 1.23-2.40). 8 Many limitations of PHILO exist, including small sample size, differences in baseline characteristics, early trial closure, and application of questionable statistics. 9 Despite many shortcomings, the findings of this study suggest a need to evaluate the lower dose of ticagrelor in East Asians, in the observance of increased bleeding compared to clopidogrel.
Maintaining an adequate antiplatelet efficacy while minimizing the risk of adverse events is crucial to the successful treatment of P2Y 12 receptor antagonists. It has been suggested that East Asian patients seem to have a different therapeutic window for platelet reactivity; while East Asians tend to result in high platelet reactivity after administration of antiplatelet agent(s), they tend to result in lower thrombotic events, which is referred to as the "East Asian paradox". 29, 30 Rationale behind such disparity of responses in East Asians compared to other races is not entirely clear, but it may be attributable to several factors, such as genetic differences and lower levels of hemostatic factors, endothelial markers, and inflammatory markers in East Asian population, which are known to be associated with risk of CV diseases. [30] [31] [32] Increased risk of bleeding in East Asians has been observed, where among patients with similar international normalized ratio values on warfarin, East Asian patients had the highest risk of intracerebral hemorrhage among other races. 33 The increase in bleeding risk could be due to smaller average body configurations of East Asians. In a study by Teng et al, 18 where the PK and PD parameters of ticagrelor were compared in Japanese and Caucasians, the average weight of the volunteers in the two groups were 64 kg and 77 kg, respectively. When the data were adjusted for body weight, the difference in systemic exposure between the two groups decreased from 40% to 14%.
Based on the analysis in this review, it was observed that PK parameters of ticagrelor and AR-C124910XX increased dose-proportionally in a predictable manner. However, with the exception of one study, 23 most PK studies only included around ten subjects per group and this resulted in widespread of the CIs. For example, in Li et al's study, 24 while the mean plasma concentrations of ticagrelor 60 mg were numerically higher than 45 mg, both of their CIs overlapped at all time points, and their differences were not considered to be significant.
Regarding PD parameters, while both low and standard ticagrelor doses alike exhibited much higher antiplatelet activity than clopidogrel in all of the four studies that also included the clopidogrel arm, three studies observed differences between the low-and standard-dose ticagrelor, while two studies observed no differences.
Previous studies 4, 28 have also evaluated the PK/PD characteristics of low dose of ticagrelor compared to the standard dose, albeit mainly in the Caucasian population. The PK and PD findings in these studies involving non-Asian patients are consistent with the findings of this review, where the PK increased in a dose-proportional manner, and this difference may but may not always translate into antiplatelet activity differences.
In terms of clinical efficacy, PEGASUS-TIMI 54 25 observed no statistical difference between the rates of primary efficacy endpoint between two ticagrelor doses (60 mg MD and 90 mg MD) after 33 months. Through the subgroup analysis, it was observed that this finding was consistent also in patients from Asia, although it should be interpreted with caution that this subgroup analysis is probably underpowered to detect significant differences among patients from 
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Evaluation of low-dose ticagrelor in East Asians different geographical regions of the world. A clinical study by Li et al 21 also included only between 108 and 132 patients per group, and it is obvious that the study did not have enough power due to the limited number of subjects.
Therefore, while dose-proportional increases in the PK parameters were observed for ticagrelor, it appears that at both low and standard doses, potent platelet inhibition occurred, which was significantly more than clopidogrel, but the degree of platelet inhibition was very high at both doses that the two different doses of ticagrelor did not always translate into PD differences. There were two clinical studies examining the differences in the outcomes of low and standard doses of ticagrelor in East Asians, but both were limited by the number of included patients. In addition, two studies included different patient populations, in that PEGASUS-TIMI 54 25 included patients 1-3 years post-MI and Li et al 21 included patients with unstable angina pectoris and nonrevascularization. Therefore, there are limited evidence available thus far to make a recommendation on clinical efficacy based on ticagrelor doses in East Asian patients. For safety outcomes, standard dose of ticagrelor, in general, resulted in higher adverse events, including bleeding rates, than the low dose of ticagrelor. 1, [19] [20] [21] 23, 24 There were studies 19, 23, 24 that reported higher rates of certain adverse events in lower doses, but the differences were mostly contributory to small number of patients included in the study and the differences in rates of bleeding were by only a few patients; therefore, the differences in rates of adverse events cannot be concluded from the currently available studies.
Limitations of this systematic review are as follows. First, this review included only studies that compared standard and low doses of ticagrelor in Asian populations, resulting in inclusion of only a limited number of articles for analysis. Second, not all of the included studies measured all PK, PD, and clinical endpoints; thus, the included studies lacked consistency in the endpoints measured. Lastly, as there were no large-scale, long-term studies on East Asian population (the longest duration was from one study with a median follow-up of 33 months), 1 it is difficult to predict the results of long-term use of low-dose ticagrelor in East Asian patients.
Conclusion
In the East Asian population, there is limited evidence available to date that compare low versus standard doses of ticagrelor to evaluate the clinical efficacy and safety. Larger and longer duration studies are warranted to more closely examine the appropriateness of lower doses of ticagrelor in this population.
